Evidence Table M2. CONTINUOUS outcomes for class ANTI-ANDROGEN.

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	M.01.01			**Cyproterone (topical)**		**Vehicle**		
141 ↓ N=45 Parallel Mild/mod		**Face severity (leeds)**	Mid (8)	Measure: 1 (0.02)		Measure: 1 (0.08)		**NS***
		Face severity change (leeds)	Mid (12)	Measure: -1 (0.11)		Measure: 0 (0.04)		**0.05**
		Total lesions (count) Count location: Excluded nose. Baseline counts: 36 (Target) / 38 (Comparator)	Mid (12)	Percent Change*: -51		Percent Change*: -28		**NS***
		Total lesions change (count)	Mid (12)	Percent change*: -75		Percent change*: -40		**0.05**
	M.01.02			**Cyproterone + ethinyl estradiol**		**Minocycline hydrochloride**		
245 ↓ N=98 Parallel Mild/mod		**Comedones (count/median)**	Mid (8)	Measure: 8		Measure: 10		
		Papules (count/median)	Mid (8)	Measure: 16		Measure: 14		
		Pustules (count/median)	Mid (8)	Measure: 8		Measure: 7		
		Comedones (count/max range)	Long (24	Measure: 63	*.01*	Measure: 327	*.01*	
		Comedones (count/median)	Long (24	Measure: 5	*.01*	Measure: 4	*.01*	
		Papules (count/max)	Long (24	Measure: 6	*.01*	Measure: 7	*.01*	
		Papules range (count/max)	Long (24	Measure: 81		Measure: 307		
		Pustules (count/max)	Long (24	Measure: 48		Measure: 189		
		Pustules (count/median)	Long (24	Measure: 2	*.01*	Measure: 2	*.01*	
	M.01.03			**Cyproterone + ethinyl estradiol + placebo**		**Tetracycline + placebo**		
137 ↑ N=92 Parallel		**Face severity change (leeds %)**	Short (6)	Measure: -29	*.001*	Measure: -25	*.001*	
		Inflammatory change (%)	Mid (8)	Percent change: -20	*.05*	Percent change: -9	*.05*	
		Non-inflammatory change (%)	Mid (8)	Percent change: -37	*.01*	Percent change: -18	*.05*	
		Total severity change (leeds %)	Mid (8)	Measure: -20	*.01*	Measure: -22	*.05*	
		Face severity change (leeds %)	Long (24	Measure: -71	*.001*	Measure: -72	*.001*	

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
137 ↑ N=92 Parallel		**Inflammatory change (%)** Between P-value: vs tetracucline alone or combined.	Long (24	Percent change: -72	*.001*	Percent change: -50	*.001*	**NS**
		Non-inflammatory change (%)	Long (24	Percent change: -76	*NS*	Percent change: -63	*.05*	
		Total severity change (leeds %) Between P-value: vs tetracucline alone or combined.	Long (24	Measure: -75	*.001*	Measure: -68	*.001*	**NS**
		Post-therapy facial severity change (leeds %)	Long (32	Measure: -72	*.001*	Measure: -55	*.01*	
		Post-therapy inflammatory change (%) Between P-value: vs cyp/ee + tet.	Long (32	Percent change: -79	*.001*	Percent change: -60	*.05*	**NS**
		Post-therapy non-inflammatory change (%)	Long (32	Percent change: -81	*.01*	Percent change: -66	*.05*	
		Post-therapy total severity change (leeds %)	Long (32	Measure: -75	*.001*	Measure: -55	*NS*	
	M.01.04			**Cyproterone + ethinyl estradiol (0.035)**		**Cyproterone (topical)**		
141 ↓ N=45 Parallel Mild/mod		**Face severity (leeds)**	Mid (8)	Measure: 1 (0.02)		Measure: 1 (0.02)		**NS***
		Total lesions (count) Baseline counts: 45 (Target) / 36 (Comparator)	Mid (8)	Percent Change*: -45		Percent Change*: -51		**NS***
		Face severity change (leeds)	Mid (12)	Measure: -1 (0.12)		Measure: -1 (0.11)		**0.05**
		Total lesions change (count) Count location: Excluded nose. Baseline counts: 45 (Target) / 36 (Comparator)	Mid (12)	Percent change*: -66		Percent change*: -75		**0.05**
	M.01.05			**Cyproterone + ethinyl estradiol (0.05)**		**Cyproterone + ethinyl estradiol (0.035)**		
48 ↑ N=133 Parallel		**Total lesions change (%)** Between P-value: vs Levonogestrel.	Long (16	Percent change: -51 (52.)		Percent change: -61 (31.)		**0.05**
117 ↓ N=73 Parallel Mod/sev		**Comedones severity (cook)** Count location: Face.	Long (24	Measure: 1	*.01*	Measure: 2	*.01*	**NS**
		Macules score (cook)	Long (24	Measure: 2	*.01*	Measure: 2	*.01*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
117 ↓ Parallel	N=73 Mod/sev	**Papules score (cook)** Count location: Face.	Long (24	Measure: 2	*.01*	Measure: 2	*.01*	**NS**
		Severity (cook)	Long (24	Measure: 2	*.01*	Measure: 2	*.01*	**NS**
48 ↑ Parallel	N=133	**Total lesions change (%)** Between P-value: vs Levonogestrel.	Long (24	Percent change: -70 (36.)		Percent change: -72 (27.)		**0.001**
66	N=96	**Severity change/patient (vas)**	Long (36	Measure: 5 (2.7)	*.001*	Measure: 5 (2.4)	*.001*	**NS**
117 ↓ Parallel	N=73 Mod/sev	**Comedones severity (cook)** Count location: Face.	Long (48	Measure: 1	*.01*	Measure: 1	*.01*	**NS**
		Macules score (cook)	Long (48	Measure: 1	*.01*	Measure: 1	*.01*	**NS**
		Papules time (cook)	Long (48	Measure: 1	*.01*	Measure: 1	*.01*	**NS**
		Severity (cook)	Long (48	Measure: 1	*.01*	Measure: 1	*.01*	**NS**
	M.01.05			**Cyproterone + ethinyl estradiol (0.05)**		**Levonorgestrel + ethinyl estradiol (0.030)**		
48 ↑ Parallel	N=133	**Total lesions change (%)** Between P-value: vs Levonogestrel.	Long (16	Percent change: -51 (52.)		Percent change: -27 (52.)		**0.05**
		Total lesions change (%)	Long (24	Percent change: -70 (36.)		Percent change: -35 (60.)		**0.001**
	M.01.06			**Cyproterone (2 mg) + ethinyl estradiol**		**Cyproterone (.05 mg) + ethinyl estradiol**		
237 Parallel	N=90 Mod/sev	**Face severity (leeds)**	Mid (8)	Measure: 1	*.01*	Measure: 1	*.001*	
		Face severity/photo Between P-value: vs norethisterone.	Mid (8)	Measure: 1		Measure: 1		**NS**
		Macules (count)	Mid (8)	Raw count: 75 (66.)		Percent Change*: 35		**NS**
		Papules (count)	Mid (8)	Raw count: 27 (37.)	*NS*	Percent Change*: -15	*NS*	**NS**
		Total severity (leeds) Between P-value: vs norethisterone.	Mid (8)	Measure: 2	*.05*	Measure: 2	*.05*	**0.05**
		Face severity (leeds)	Long (26	Measure: 1	*.001*	Measure: 0	*.001*	**0.001**
		Face severity/photo	Long (26	Measure: 1		Measure: 0		**0.001**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
237 Parallel	N=90 Mod/sev	**Nodules (count)** Between P-value: "worse than cyproterone (50) " P.05.	Long (26	Raw count: 39 (64.)		Raw count: 21 (45.)		**NS***
		Papules (count)	Long (26	Raw count: 15 (18.)	*.005*	Percent Change*: -79	*.001*	**NS***
		Total severity (leeds) Between P-value: vs norethisterone.	Long (26	Measure: 1	*.001*	Measure: 1	*.001*	**0.05**
	M.01.07			**Cyproterone + ethinyl estradiol (0.035)**		**Desogestrel + ethinyl estradiol**		
87 ↓ Parallel	N=183 Mild	**Comedones change (count/median)**	Long (16	Measure: -6		Measure: -3		
		Papules change (count/median)	Long (16	Measure: -5		Measure: -5		
		Pustules change (count/median)	Long (16	Measure: -3		Measure: -2		
		Severity (leeds)	Long (16	Measure: 1 (0.53)		Measure: 0 (0.42)		**NS***
		Severity change (dieben/median)	Long (16	Measure: 0 (0.53)		Measure: 0 (0.45)		**NS***
	M.01.07			**Desogestrel + ethinyl estradiol**		**Cyproterone + ethinyl estradiol (.05)**		
55 ↓ Parallel	N=66	**Severity [center a] (charoenvisal)** Count location: Face.	Short (4)	Measure: 2	*NS*	Measure: 2	*NS*	**NS**
		Severity [center b] (charoenvisal)	Short (4)	Measure: 2	*NS*	Measure: 2	*NS*	**NS**
		Severity [center a] (charoenvisal)	Mid (12)	Measure: 1	*NS*	Measure: 1	*.05*	**NS**
		Severity [center b] (charoenvisal)	Mid (12)	Measure: 2	*.05*	Measure: 2	*NS*	**NS**
		Severity [center a] (charoenvisal)	Long (24	Measure: 2	*NS*	Measure: 1	*.05*	**0.05**
		Severity [center b] (charoenvisal)	Long (24	Measure: 1	*.01*	Measure: 1	*.001*	**NS**
	M.01.08			**Cyproterone + ethinyl estradiol (0.035)**		**Levonorgestrel + ethinyl estradiol (0.030)**		
48 ↑ Parallel	N=133	**Total lesions change (%)**	Long (16	Percent change: -61 (31.)		Percent change: -27 (52.)		**NS**
		Total lesions change (%) Between P-value: vs Levonogestrel.	Long (24	Percent change: -72 (27.)		Percent change: -35 (60.)		**0.001**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	M.01.09			**Cyproterone (.05 mg) + ethinyl estradiol**		**Norethisterone + placebo + ethinyl estradiol**		
237 Parallel	N=90 Mod/sev	**Face severity (leeds)** Between P-value: vs norethisterone.	Mid (8)	Measure: 1	*.001*	Measure: 1	*.001*	**0.05**
		Face severity/photo	Mid (8)	Measure: 1		Measure: 1		**0.05**
		Macules (count) Baseline counts: 43 (Target) / (Comparator)	Mid (8)	Percent Change*: 35		Raw count: 56 (64.)		**NS**
		Papules (count) Baseline counts: 27 (Target) / 30 (Comparator)	Mid (8)	Percent Change*: -15	*NS*	Percent Change*: -10	*NS*	**NS**
		Total severity (leeds) Between P-value: vs norethisterone.	Mid (8)	Measure: 2	*.05*	Measure: 3	*NS*	**0.01**
		Face severity (leeds)	Long (26	Measure: 0	*.001*	Measure: 1	*.001*	**0.001**
		Face severity/photo	Long (26	Measure: 0		Measure: 1		**0.001**
		Nodules (count)	Long (26	Raw count: 21 (45.)		Percent Change*: 26		**NS***
		Papules (count) Baseline counts: 27 (Target) / 30 (Comparator)	Long (26	Percent Change*: -79	*.001*	Percent Change*: -34	*NS*	**NS***
		Total severity (leeds) Between P-value: vs norethisterone.	Long (26	Measure: 1	*.001*	Measure: 2	*.05*	**0.01**
	M.02.01			**Desogestrel + ethinyl estradiol**		**Gestodene + ethinyl estradiol**		
225 ↓ Parallel	N=24 Mild/mod	**Severity/arm (pillsbury)** Count location: Each side of face.	Mid (12)	Measure: 2		Measure: 2		
		Severity/arm (pillsbury)	Long (36	Measure: 1	*.05*	Measure: 1	*.02*	
	M.02.02			**Desogestrel + ethinyl estradiol**		**Levonorgestrel + ethinyl estradiol**		
264 ↑ Parallel	N=33 Mild/mod	**Severity (allen-smith)**	Long (24	Measure: 1 (0.55)	*.001*	Measure: 1 (0.56)	*.01*	**0.05**
	M.03.01			**Spironolactone**		**Placebo**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
249 ↑ N=58 Cross-over Mild/mod		**Total lesions [phase i+phase ii] (count)** Baseline counts: 38 (Target) / 24 (Comparator)	Mid (12)	Percent Change*: -66		Percent Change*: 05		**0.001**
	M.04.06			**Inocoterone acetate**		**Vehicle**		
213 ↑ N=153 Parallel Mod		**Comedones (count)** Baseline counts: 22 (Target) / 26 (Comparator)	Short (4)	Percent Change*: 05		Percent Change*: -19		**NS**
		Inflammatory (count) Baseline counts: 26 (Target) / 27 (Comparator)	Short (4)	Percent Change*: -15		Percent Change*: -11		**NS**
		Comedones (count) Baseline counts: 22 (Target) / 26 (Comparator)	Mid (12)	Percent Change*: -09		Percent Change*: -12		**NS**
		Inflammatory (count) Baseline counts: 26 (Target) / 27 (Comparator)	Mid (12)	Percent Change*: -23		Percent Change*: -15		**0.019**
		Comedones (count) Baseline counts: 22 (Target) / 26 (Comparator)	Long (16	Percent Change*: -09		Percent Change*: -19		**NS**
		Inflammatory (count) Baseline counts: 26 (Target) / 27 (Comparator)	Long (16	Percent Change*: -31		Percent Change*: -15		**0.025**
	M.04.09			**Norgestimate + ethinyl estradiol + inactive drug**		**Placebo**		
218 ↑ N=257 Parallel Mod		**Total lesions change (%)**	Mid (12)	Percent change: -33		Percent change: -22		**NS**
		Total lesions change (%)	Long (24	Percent change: -53 (29.9)		Percent change: -27 (43.7)		**0.0001**
280 ↑ N=250		**Comedones change (count)** Count location: Face. Baseline counts: 37 (Target) / 38 (Comparator)	Long (26	Percent change*: 40		Percent change*: 34		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
218 ↑ N=257 Parallel Mod		**Comedones change (count)** Baseline counts: 35 (Target) / 30 (Comparator)	Long (26	Percent change*: 49		Percent change*: 22		**0.0003**
		Inflammatory (count) Baseline counts: 19 (Target) / 20 (Comparator)	Long (26	Percent Change*: -39		Percent Change*: -62		**0.0001**
280 ↑ N=250		**Inflammatory change (count)** Baseline counts: 19 (Target) / 19 (Comparator)	Long (26	Percent change*: 49		Percent change*: 35		**0.02**
218 ↑ N=257		**Nodules change (count)** Baseline counts: 0 (Target) / 0 (Comparator)	Long (26	Percent change*: 33		Percent change*: 00		**NS**
280 ↑ N=250		**Total lesions change (count)** Count location: Face. Baseline counts: 56 (Target) / 57 (Comparator)	Long (26	Percent change*: 43		Percent change*: 34		**NS**
	M.04.10			**Quinestradol**		**Placebo**		
248 ↓ N=60 Parallel Mild/mod		**Comedones (count)** Count location: Left side. Baseline counts: 32 (Target) / 28 (Comparator)	Mid (8)	Percent Change*: -50	*.01*	Percent Change*: -29	*NS*	**NS***
		Total lesions (count) Count location: Left side.	Mid (8)	Raw count: 22 (15.6)	*.001*	Raw count: 27 (18.3)	*.01*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.